Helixmith, Catexcel, and GI Cell Collaborate on CGT Joint Research

Hongcheon-pyo, CEO of GI Cell, Yuseung-shin, CEO of Helixmith, and Seoje-hee, CEO of Cartexel (from left), are posing for a commemorative photo after signing a business agreement for joint research on cell and gene therapy (CGT).

[Asia Economy Reporter Lee Chun-hee] Helixmith is partnering with Cartexel and GI Cell to jointly research cell and gene therapies (CGT).

Helixmith announced on the 28th that it signed a tripartite memorandum of understanding (MOU) for CGT joint research at GI Cell's headquarters in Seongnam-si, Gyeonggi Province on the 27th. The signing ceremony was attended by key stakeholders including Yoo Seung-shin, CEO of Helixmith, Seo Je-hee, CEO of Cartexel, and Hong Cheon-pyo, CEO of GI Cell.

Going forward, the three companies plan to collaborate on deriving CGT candidate substances, manufacturing clinical trial drugs, and commercialization. Accordingly, Helixmith's CGT Center will provide technology and one-stop services for CGT development and production, Cartexel will contribute CAR-T cell therapy technology, and GI Cell will offer immune cell culture and freezing systems, with the three companies aiming to lead the CGT market together.

Yoo Seung-shin, CEO of Helixmith, said, "We expect to demonstrate differentiated competitiveness in the CGT business through this MOU," adding, "We will continue to make various agreements to leap forward as a global gene therapy company representing South Korea in the world market." Seo Je-hee, CEO of Cartexel, also stated, "Through the convergence of Helixmith and Cartexel's CAR gene engineering and delivery technologies and GI Cell's differentiated immune cell culture technology, we expect to secure a CAR-NK cell therapy pipeline early."

This content was produced with the assistance of AI translation services.